Blog

Distal clavicle osteolysis is shoulder joint pain at the end of the collarbone that is the result of bone disintegration and damage. The most common symptom is a sharp or aching pain at the junction of the acromioclavicular joint (AC joint) and collarbone.

The bicep muscle is one of the most important muscles for your upper body strength. An injury to this hardworking muscle can make day-to-day tasks difficult.

A procedure that "stuns" pain-sensing nerves might offer relief to people with severe arthritis of the hip or shoulder, a small, preliminary study suggests.

Orthopaedic surgery techniques for treatment of recurrent shoulder instability are effective, but prone to problems with nonunion of bone grafts held ...

This study aimed to determine the function of the acetabular fossa. The morphology and physiology of the fossa may play a role in decision-making for hip preservation surgery. We aimed to determine if the acetabular fossa has a biological capacity of response to pre-arthritic and arthritic hip disea...

Hip pain is a common problem, and it can be confusing because there are many causes, including a hyperextended hip, arthritis, or a fracture. It is important that you seek medical attention for your hip pain so the cause of your symptoms can be identified and appropriate treatment can be directed at...

Femoroacetabular impingement (FAI) is a condition characterized by the abnormal shape of the ball-and-socket hip joint. FAI is associated with hip-joint arthritis, and there are a number of different treatment options.

Osteoporosis is a chronic condition caused by the loss of bone density. You can reverse the loss of bone density with medical therapies that may slow, maintain, or even increase your bone density.

In the older male population, there is a high level of underdiagnosis and undertreatment of osteoporosis, according to a study presented at ACR Convergence, the annual meeting of the American College of Rheumatology, held virtually from Nov. 5 to 9.

For women who have received five years of bisphosphonate therapy, hip fracture risk does not differ with continuing treatment for an additional five years versus discontinuing treatment, according to a study published online Dec. 7 in JAMA Network Open.